Zacks Research Comments on ResMed Inc.’s Q1 2025 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Equities researchers at Zacks Research increased their Q1 2025 earnings per share (EPS) estimates for ResMed in a research report issued on Thursday, August 22nd. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $2.02 for the quarter, up from their prior forecast of $1.97. The consensus estimate for ResMed’s current full-year earnings is $8.72 per share. Zacks Research also issued estimates for ResMed’s Q2 2025 earnings at $2.16 EPS, Q3 2025 earnings at $2.22 EPS, FY2025 earnings at $8.68 EPS, Q1 2026 earnings at $2.18 EPS, Q2 2026 earnings at $2.24 EPS, Q3 2026 earnings at $2.40 EPS, Q4 2026 earnings at $2.44 EPS, FY2026 earnings at $9.26 EPS and FY2027 earnings at $10.11 EPS.

Several other analysts also recently issued reports on RMD. StockNews.com upgraded ResMed from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and issued a $236.00 price objective on shares of ResMed in a research report on Friday, August 2nd. Royal Bank of Canada raised their price objective on ResMed from $204.00 to $206.00 and gave the stock a “sector perform” rating in a report on Friday, August 2nd. Oppenheimer lowered ResMed from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 25th. Finally, Citigroup downgraded shares of ResMed from a “buy” rating to a “neutral” rating in a report on Monday, June 24th. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $204.70.

ResMed Price Performance

RMD stock opened at $226.64 on Monday. The stock’s 50 day moving average price is $207.17 and its 200 day moving average price is $200.49. The firm has a market cap of $33.30 billion, a P/E ratio of 34.81, a PEG ratio of 2.31 and a beta of 0.66. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.69 and a current ratio of 2.59. ResMed has a 1 year low of $132.24 and a 1 year high of $231.50.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, August 1st. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.03 by $0.05. ResMed had a net margin of 21.79% and a return on equity of 25.00%. The company had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.22 billion. During the same quarter in the previous year, the business posted $1.60 earnings per share. The firm’s quarterly revenue was up 6.9% compared to the same quarter last year.

Institutional Trading of ResMed

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in ResMed by 24.9% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 177,083 shares of the medical equipment provider’s stock worth $35,068,000 after purchasing an additional 35,273 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in ResMed by 8.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 536,459 shares of the medical equipment provider’s stock valued at $92,285,000 after buying an additional 40,605 shares during the last quarter. ICW Investment Advisors LLC raised its stake in ResMed by 2.3% during the fourth quarter. ICW Investment Advisors LLC now owns 11,303 shares of the medical equipment provider’s stock valued at $1,944,000 after buying an additional 249 shares in the last quarter. Los Angeles Capital Management LLC lifted its holdings in ResMed by 647.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 13,491 shares of the medical equipment provider’s stock worth $2,321,000 after buying an additional 11,685 shares during the last quarter. Finally, Mediolanum International Funds Ltd acquired a new position in shares of ResMed in the 1st quarter worth approximately $2,246,000. 54.98% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at ResMed

In related news, General Counsel Michael J. Rider sold 882 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $231.00, for a total value of $203,742.00. Following the completion of the sale, the general counsel now directly owns 10,512 shares in the company, valued at approximately $2,428,272. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CFO Brett Sandercock sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $209.81, for a total transaction of $209,810.00. Following the transaction, the chief financial officer now directly owns 91,056 shares of the company’s stock, valued at approximately $19,104,459.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Michael J. Rider sold 882 shares of the firm’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $231.00, for a total transaction of $203,742.00. Following the sale, the general counsel now directly owns 10,512 shares of the company’s stock, valued at $2,428,272. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 95,931 shares of company stock worth $20,326,437. 1.21% of the stock is currently owned by corporate insiders.

ResMed Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 19th. Stockholders of record on Thursday, August 15th will be given a $0.53 dividend. The ex-dividend date is Thursday, August 15th. This represents a $2.12 annualized dividend and a dividend yield of 0.94%. This is a positive change from ResMed’s previous quarterly dividend of $0.48. ResMed’s dividend payout ratio is presently 32.57%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.